AstraZeneca Other Non-Current Liabilities 2010-2024 | AZN

AstraZeneca other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • AstraZeneca other non-current liabilities for the quarter ending June 30, 2024 were $3.343B, a 12.56% decline year-over-year.
  • AstraZeneca other non-current liabilities for 2023 were $3.825B, a 28.24% decline from 2022.
  • AstraZeneca other non-current liabilities for 2022 were $5.33B, a 10.18% decline from 2021.
  • AstraZeneca other non-current liabilities for 2021 were $5.934B, a 11.03% decline from 2020.
AstraZeneca Annual Other Non-Current Liabilities
(Millions of US $)
2023 $3,825
2022 $5,330
2021 $5,934
2020 $6,670
2019 $7,150
2018 $7,159
2017 $8,191
2016 $9,958
2015 $7,902
2014 $8,475
2013 $2,919
2012 $1,429
2011 $859
2010 $1,216
2009 $4,075
AstraZeneca Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-06-30 $3,343
2024-03-31 $3,770
2023-12-31 $3,825
2023-09-30 $3,508
2023-06-30 $3,823
2023-03-31 $4,447
2022-12-31 $5,330
2022-09-30 $6,102
2022-06-30 $5,082
2022-03-31 $4,752
2021-12-31 $5,934
2021-09-30 $5,872
2021-06-30 $5,815
2021-03-31 $5,725
2020-12-31 $6,670
2020-09-30 $7,327
2020-06-30 $7,100
2020-03-31 $7,216
2019-12-31 $7,150
2019-09-30 $7,893
2019-06-30 $7,351
2019-03-31 $7,259
2018-12-31 $7,159
2018-09-30 $8,284
2018-06-30 $8,470
2018-03-31 $8,357
2017-12-31 $8,191
2017-09-30 $10,197
2017-06-30 $9,780
2017-03-31 $9,981
2016-12-31 $9,958
2016-09-30 $11,263
2016-06-30 $11,471
2016-03-31 $11,086
2015-12-31 $7,902
2015-09-30 $8,337
2015-06-30 $8,458
2015-03-31 $8,600
2014-12-31 $8,475
2014-09-30 $7,463
2014-06-30 $7,530
2014-03-31 $7,730
2013-12-31 $2,919
2013-09-30 $1,702
2013-06-30 $1,655
2013-03-31 $1,715
2012-12-31 $1,429
2012-09-30 $1,606
2012-06-30 $1,680
2012-03-31 $1,003
2011-12-31 $859
2011-09-30 $1,060
2011-06-30 $1,155
2011-03-31 $1,071
2010-12-31 $3,688
2010-09-30 $4,837
2010-06-30 $4,184
2010-03-31 $3,969
2009-12-31 $4,075
2009-09-30 $3,667
2009-06-30 $3,782
2009-03-31 $3,821
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51